HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sally Beauty names new VP, treasurer

This article was originally published in The Rose Sheet

Executive Summary

Sally Beauty Holdings names J. Gregory Coffey VP and treasurer, effective immediately, firm reports April 26. In his new position, Coffey will be responsible for overseeing the company's capital markets activity; he also will handle cash management, risk management and financial planning and analysis for the firm. Prior to joining Sally Beauty Holdings, Coffey - who has 19 years of treasury and finance experience - served as CFO of Dean & Deluca in Wichita, Kan. He also served as VP and treasurer of Pier 1 Imports' U.S. business and has held management positions in finance and treasury at Electronic Data Systems Corporation and American Airlines, firm adds. Coffey will report to David Rea, senior VP and CFO...

You may also be interested in...



Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Dr Reddy’s Knocked Back On Rituximab In US

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Sandoz And Samsung Celebrate Stelara Rival’s EU Approval

Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel